Milestone in Global Health: First Malaria Treatment for Infants Approved

Wed Jul 09 2025 17:32:41 GMT+0300 (Eastern European Summer Time)
Milestone in Global Health: First Malaria Treatment for Infants Approved

A groundbreaking malaria treatment specifically for infants has received approval, aiming to address the high mortality rate among young children in Africa.


The launch of the first malaria treatment designed for babies, developed by Novartis, is set to commence in African nations soon, promising significant advancements in combating the disease which claims thousands of young lives annually.



The approval of the first malaria treatment specifically designed for infants and very young children marks a significant milestone in global health efforts. This new drug, developed by Novartis, is expected to be distributed in African countries in the coming weeks. Previously, infants suffering from malaria had to rely on medications formulated for older children, which posed a risk of overdose due to their developing livers and differing body dynamics.

In 2023, malaria was responsible for approximately 597,000 deaths, with the majority occurring in Africa and about 75% of those fatalities involving children under five. The lack of appropriate treatments for the youngest patients led to what health experts have termed a "treatment gap."

The newly approved medicine, referred to as Coartem Baby or Riamet Baby in different regions, was developed in collaboration with the Medicines for Malaria Venture (MMV) — a non-profit organization supported by various governments and institutions, including the British, Swiss, and Dutch governments. The drug has been designed specifically for those weighing less than 4.5 kg (roughly 10 lbs), a demographic previously underserved in malaria care.

Novartis's chief executive, Vas Narasimhan, emphasized the significance of this development in the ongoing fight against malaria, expressing pride in the partnership that led to creating an optimized treatment for the world's tiniest and most vulnerable population.

MMV’s CEO, Martin Fitchet, hailed the approval as a critical step toward reducing the burden of malaria, especially among children, while Dr. Marvelle Brown from the University of Hertfordshire underscored the need for adequate healthcare access for those infants with compromised immune systems due to conditions like sickle cell disease.

As the drug is rolled out on a largely non-profit basis, health officials are hopeful that it will not only save countless lives but also enhance equity in healthcare access across regions most affected by malaria.

MORE ON THEME

Tue, 08 Jul 2025 06:14:03 GMT

**First Malaria Treatment for Infants Gains Approval in Major Breakthrough**

Tue, 08 Jul 2025 06:14:03 GMT
Fri, 04 Jul 2025 05:29:27 GMT

Manila's Mayor Faces Garbage Crisis upon Return to Office

Fri, 04 Jul 2025 05:29:27 GMT
Fri, 04 Jul 2025 03:49:56 GMT

Angélique Kidjo Shines as First Black African Star on Hollywood's Walk of Fame

Fri, 04 Jul 2025 03:49:56 GMT
Tue, 01 Jul 2025 21:01:36 GMT

Trump Administration's Aid Cuts Could Lead to Catastrophic Death Toll, New Report Warns**

Tue, 01 Jul 2025 21:01:36 GMT
Tue, 01 Jul 2025 13:14:49 GMT

Analyzing RFK Jr.'s Controversial Health Initiative: Promise or Peril?

Tue, 01 Jul 2025 13:14:49 GMT
Tue, 01 Jul 2025 09:38:49 GMT

Measles Resurgence: Understanding Risks and Prevention Strategies This Summer

Tue, 01 Jul 2025 09:38:49 GMT
Tue, 01 Jul 2025 08:25:57 GMT

RFK Jr's Vision: Health Revolution or Fearmongering in American Policy?

Tue, 01 Jul 2025 08:25:57 GMT
Mon, 30 Jun 2025 19:34:36 GMT

Calgary Reinstates Fluoride in Drinking Water Following Health Concerns

Mon, 30 Jun 2025 19:34:36 GMT
Sun, 29 Jun 2025 19:36:39 GMT

**Trump Celebrates Political Victories Amid Ongoing Challenges**

Sun, 29 Jun 2025 19:36:39 GMT
Sat, 28 Jun 2025 13:56:07 GMT

**Trump's Surge Amid Political Wins and Continued Challenges**

Sat, 28 Jun 2025 13:56:07 GMT
Thu, 26 Jun 2025 00:59:23 GMT

Thailand Implements New Cannabis Regulations Amid Smuggling Concerns

Thu, 26 Jun 2025 00:59:23 GMT
Wed, 25 Jun 2025 09:35:14 GMT

Challenges in HIV Prevention as US Support Dwindles**

Wed, 25 Jun 2025 09:35:14 GMT
Fri, 20 Jun 2025 17:44:26 GMT

Fatal Food Poisoning Outbreak in Northern France: Butchers Closed Following Child's Death

Fri, 20 Jun 2025 17:44:26 GMT
Tue, 17 Jun 2025 11:27:51 GMT

North Korea's COVID-19 'Victory' Revealed as Falsehood, Says New Report

Tue, 17 Jun 2025 11:27:51 GMT
Sun, 15 Jun 2025 17:20:41 GMT

Nationwide Protests Erupt Against Trump Amid Military Parade

Sun, 15 Jun 2025 17:20:41 GMT
Sun, 15 Jun 2025 07:49:16 GMT

Nationwide Protests Erupt as Trump Celebrates Military Parade

Sun, 15 Jun 2025 07:49:16 GMT
Fri, 13 Jun 2025 21:03:56 GMT

Surge of Mpox Cases in Sierra Leone Amid Appeals for Global Aid

Fri, 13 Jun 2025 21:03:56 GMT
Thu, 12 Jun 2025 15:02:21 GMT

Journey to Recovery: Malnourished Baby Siwar Evacuated from Gaza to Jordan

Thu, 12 Jun 2025 15:02:21 GMT
Wed, 11 Jun 2025 17:58:54 GMT

Young Survivor of Gaza Airstrike Flown to Italy for Medical Care

Wed, 11 Jun 2025 17:58:54 GMT
Mon, 09 Jun 2025 16:53:38 GMT

Iran Reaffirmed Dog Walking Ban Amid Growing Enforcement

Mon, 09 Jun 2025 16:53:38 GMT

Follow us

© 2024 SwissX REDD UK ltd. All Rights Reserved.